PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2013; 8(9): e71557.
Published online 2013 September 24. doi:  10.1371/journal.pone.0071557
PMCID: PMC3782474

HIV-1 Transmission during Early Antiretroviral Therapy: Evaluation of Two HIV-1 Transmission Events in the HPTN 052 Prevention Study

Zandrea Ambrose, Editor

Abstract

In the HPTN 052 study, transmission between HIV-discordant couples was reduced by 96% when the HIV-infected partner received suppressive antiretroviral therapy (ART). We examined two transmission events where the newly infected partner was diagnosed after the HIV-infected partner (index) initiated therapy. We evaluated the sequence complexity of the viral populations and antibody reactivity in the newly infected partner to estimate the dates of transmission to the newly infected partners. In both cases, transmission most likely occurred significantly before HIV-1 diagnosis of the newly infected partner, and either just before the initiation of therapy or before viral replication was adequately suppressed by therapy of the index. This study further strengthens the conclusion about the efficacy of blocking transmission by treating the infected partner of discordant couples. However, this study does not rule out the potential for HIV-1 transmission to occur shortly after initiation of ART, and this should be recognized when antiretroviral therapy is used for HIV-1 prevention.

Introduction

Combination antiretroviral therapy (ART) reduces HIV-1 RNA levels in blood and genital secretions [1], [2], [3]. The probability of HIV-1 transmission is related to HIV-1 RNA levels in the plasma [4], [5] and the genital tract [6]. For these reasons, it seemed likely that treatment of an infected person with ART would reduce transmission to a sexual partner. Several observational studies supported this idea [7], [8], [9], [10]. The HPTN 052 study was specifically designed to measure the degree to which suppressive treatment of an HIV-infected person in a discordant relationship could prevent sexual transmission [4]. In HPTN 052, HIV-infected partners (index) with CD4+ T cell counts >350 and <550 cells/ul, were randomized to receive immediate ART (early ART arm), or to receive ART when their CD4+ T cell count dropped to >200 and <250 cells/ul (delayed ART arm). The study was unblinded in April, 2011. At that time, 27 of 28 virologically-linked transmission events [11] were found to have occurred in the delayed ART arm, demonstrating a greater than 96% reduction in HIV-1 transmission over a median of 1.7 years, ascribed to early ART initiation. However, two transmission events raised the possibility that transmission might still occur after ART initiation: one virologically-linked transmission event in the early ART arm (Case A, 052–1168), and one virologically-linked transmission event in the delayed ART arm that occurred after the index initiated ART in response to a falling CD4+ T cell count (Case B, 052–2899) [11]. We evaluated the timing of HIV-1 transmission in these two cases by analyzing the viral sequence complexity and antibody response in the newly infected partners.

Materials and Methods

Ethics statement

This research was performed with appropriate IRB approval which was obtained from 36 different reviewing entities, included in Supporting Information S1. Written informed consent was provided, by all participants.

Plasma samples were collected in the HPTN 052 study. Methods used in the trial for HIV-1 diagnosis and HIV-1 viral load testing were described previously [4]. The extent of maturation of the antibody response was determined by examining the pattern of reactivity with viral proteins in ELISA and western blot format assays; antibody reactivity was interpreted using the timing scale described in Fiebig et al. [12].

HIV-1 RNA was extracted from the plasma samples using the QIAamp Viral RNA Mini Kit (QIAGEN), and was reverse transcribed to produce cDNA using Superscript III Reverse Transcriptase (Invitrogen) and an oligo dT primer. Polymerase Chain Reaction (PCR) amplicons were generated from single cDNA templates using an endpoint dilution strategy [13]; primers were tailored for amplification of the env gene from subtype C HIV-1, since both transmission events involved subtype C virus [11]. For each sample, approximately 20 full-length env amplicons were generated.

Sequences obtained from those amplicons were used to generate phylogenetic trees using the program BEAST (Bayesian Evolutionary Analysis by Sampling Trees) [14]. BEAST uses a Bayesian Markov Chain Monte Carlo approach, implemented using the program BEAST v.1.6.1 [14], which was used to estimate the time to the most recent common ancestor (MRCA) for each sample. For Case A, this analysis was performed using just the major viral population. We used a fixed mutation rate (1.5×10−5) which we have found useful in defining time since transmission for a number of recent transmission events (unpublished data). We also used tip dating given the known dates of sampling, which allowed an output in days rather than generations. Accession numbers for the env gene sequences used in the BEAST analysis are KC634109-KC634205.

A second approach, the Poisson Fitter [15], was also used to estimate the extent of early evolution in Case A. The Poisson Fitter was implemented at http://www.hiv.lanl.gov/content/sequence/POISSON_FITTER/poisson_fitter.html using the sequences from the major viral population. A mutation rate of 2.16×10−5 per site per generation was used in the model.

Results and Discussion

First, we evaluated results obtained from HIV-1 RNA load testing and Western blot testing for anti-HIV antibodies (note that ART initiation is indicated as Day 0; negative numbers indicate days before ART initiation and positive numbers indicate days after ART initiation). In Case A, the partner had undetectable HIV-1 RNA load (<40 copies/ml) at Day −35 and a positive Western blot on Day +35 (Figure 1A). In Case B, the partner had undetectable HIV-1 RNA load on Day −1 and a positive Western blot on Day +84 (Figure 1A). Assuming a 7-day eclipse period between HIV-1 infection and the detection of HIV-1 RNA in plasma, transmission in Case A must have occurred after Day −42 (i.e., an outer limit of 7 days before the last negative sample), and transmission in Case B must have occurred after Day −8. Virologic suppression was first documented in the index at Day +30 and Day +27 for Case A and B, respectively (Figure 1A). This simple analysis indicates that transmission in both cases could have occurred before ART was initiated, or after ART initiation but before virologic suppression occurred.

Figure 1
Timeline and summary of data estimating dates of transmission relative to the initiation of therapy.

The dates of transmission were defined further by analyzing viral populations and the antibody response to infection in samples from the newly infected partners to estimate the length of time the newly infected partners had been infected. Viral populations were analyzed using plasma samples collected from the index prior to ART initiation (Case A: Day −38; Case B: Day −1) and plasma samples collected from the newly infected partners on the day of HIV-1 diagnosis (Case A: Day +35; Case B: Day +84).

Evaluation of transmission in Case A

In Case A, the partner was diagnosed with HIV-1 infection 35 days after the index initiated ART (Day +35). Phylogenetic analysis of viral sequences from the index at Day −38 was consistent with a chronic HIV-1 infection (i.e., a complex pattern of HIV-1 variants with significant sequence diversity); in contrast, phylogenetic analysis of viral sequences from the newly-infected partner revealed one major population that was genetically homogeneous and three minor viral populations indicating the transmission of at least four variants (Figure 2A). The limited genetic diversity in the major viral population from the newly infected partner suggested that HIV-1 infection occurred close to the time of HIV-1 diagnosis.

Figure 2
Phylogenetic analysis of viral populations in the index and partner.

We used BEAST analysis [14] of the major viral population in the newly-partner to estimate the number of days between HIV-1 infection (i.e. the number of days since this lineage existed as a single sequence, referred to as the time to the most recent common ancestor, MRCA) and HIV-1 diagnosis. The time to the MRCA was estimated to be 40 days (95% CI: 25, 53 days, Table 1, Figure 2A). This corresponds to an estimated transmission 5 days before the index started ART (Day −2, 95% CI: Day –18, Day +20).

Table 1
Data obtained using BEAST analysis, the Poisson Fitter tool, and serological analysis are expressed as the number of days between the estimated date of HIV-1 transmission and HIV-1 diagnosis in the newly-infected partner. These data are also shown in ...

We also used the Poisson Fitter Tool [15] to estimate the time since transmission of the major population and HIV-1 diagnosis. This tool estimates the number of viral generations based on the accumulation of neutral mutations, which are observed before selection on viral sequences by the host immune response [15]. With this tool, we estimated that the partner was infected 34 days prior to HIV-1 diagnosis (95% CI: 22, 45 days, Table 1). This corresponds to transmission one day after the index started ART (Day +1, 95% CI: Day −10, Day +13), which is close to the estimate provided by BEAST analysis.

As an independent measure of the timing of transmission, we examined the HIV-1 antibody response in the newly infected partner. In Case A, the antibody reactivity pattern in the Western blot at the time of HIV-1 diagnosis was Fiebig Stage V [12], displaying broad reactivity to viral proteins but without reactivity to the integrase protein p31. This reactivity pattern appears after Fiebig Stage IV, which lasts on average until 19 days, but can be as short as 15 days after HIV-1 RNA is detectable in the blood, or approximately 26 days, but as early a 22 days, after transmission after including a 7-day eclipse period. Thus, Fiebig stage V can start as early as 23 days after infection and persists on average about 70 days. Based on these serologic findings, the newly infected partner was likely to have been infected at least at least 23 days prior to HIV-1 diagnosis (Table 1); this corresponds to transmission occurring on or before Day +12.

Figure 1B shows a summary of the time estimates associated with this transmission event relative to the time of ART initiation in the index (Day 0). In this case, data obtained from three separate measures (sequence complexity using BEAST, sequence complexity using Poisson Fitter, and serology) indicate that this transmission event occurred significantly before HIV-1 diagnosis, before or shortly after the index initiated ART.

Evaluation of transmission in Case B

In Case B, the partner was diagnosed with HIV-1 infection 84 days after the index initiated ART (Day +84). Phylogenetic analysis of sequences from the index at Day −1 was consistent with a chronic HIV-1 infection; in contrast, sequences from the newly infected partner represented a single, monophyletic lineage, consistent with transmission of a single HIV-1 variant (Figure 2B). This population had a much higher level of diversity than the major viral population in Case A, suggesting that a longer time had elapsed between HIV-1 transmission and HIV-1 diagnosis in Case B.

We used BEAST analysis to estimate the number of days between HIV-1 infection and HIV-1 diagnosis in the newly infected partner in Case B. The time to the MRCA was estimated to be 84 days (95% CI: 65, 116 days, Table 1, Figure 2B). This corresponds to transmission on the day the index started ART (Day 0, 95% CI: Day −24, Day +19). It is unlikely the transmission took place earlier than Day −8 given the negative HIV-1 RNA test on Day −1, and the BEAST analysis is consistent with transmission occurring prior to Day +19. In Case B, we did not use the Poisson Fitter tool to provide an independent estimate of the timing of transmission. This tool was designed to measure the accumulation of neutral mutations that are observed before the viral population is subjected to strong selective pressure. Given the complexity of the sequences in the newly infected partner in Case B, we chose not to use Poisson Fitter.

We also examined the HIV-1 antibody response in the newly infected partner. Consistent with the greater genetic complexity of the population in this newly infected partner, results from antibody reactivity in Western blot analysis suggested a more mature host immune response. The reactivity pattern for this partner was consistent with Fiebig Stage VI, reflecting the presence of anti-HIV antibodies that included reactivity to the p31 integrase protein. On average, reactivity to p31 does not appear until 90 days after HIV-1 RNA is detectable, but can appear as early as 48 days after HIV-1 RNA detection. Assuming a 7-day eclipse period, the finding of Fiebig stage VI reactivity in this participant indicates that transmission could have occurred as early as 55 days before HIV-1 diagnosis (Table 1), or Day +29. Transmission could have occurred even before this date since Fiebig Stage VI represents the terminal stage in this scale. These serologic findings are consistent with findings based on viral genetic analysis.

Data obtained for Case B are summarized in Figure 1B. In this case, as in Case A, it is most likely that HIV-1 transmission occurred either before ART initiation, or shortly after ART initiation. However, the longer time interval between ART initiation in the index and HIV-1 diagnosis in the partner (84 days, compared to 35 days in Case A) adds an increased level of uncertainty in estimating the timeframe within which transmission occurred.

Conclusions

The HPTN 052 study provided unequivocal evidence that ART can prevent HIV-1 transmission [4]. This has led to substantial changes in public policy (www.pepfar.gov/documents/organization/177126.pdf) and has inspired several studies to determine the population level effects of ART for prevention. Results from the HPTN 052 study will determine the durability of ART for prevention. In this report, we demonstrate that two HIV-1 transmission events in HPTN 052 that were documented after the index initiated ART most likely occurred either shortly before ART initiation or before ART could sufficiently suppress viral replication in the genital tract. Combination antiretroviral therapy still requires several weeks for suppression of HIV-1 in blood [2]. These results indicate that HIV-infected patients beginning ART should be informed that several weeks of ART may be needed before the risk of HIV-1 transmission is significantly reduced [4]. Documentation that these two transmission events were likely to have occurred before or shortly after ART initiation (prior to virologic suppression) provides further evidence of the efficacy of suppressive ART for prevention of HIV-1 transmission in serodiscordant couples.

Supporting Information

Supporting information S1

(PDF)

Acknowledgments

The authors thank the staff at the study sites and at the HPTN Network Laboratory for assistance with sample management.

Funding Statement

This work was supported by National Institutes of Health grants to the HIV Prevention Trials Network (HPTN) (U01-AI068619/UM1-AI068619), the HPTN Network Laboratory (U01-AI068613/UM1-AI068613), the HPTN Statistical and Data Management Center (U01-AI068617/UM1-AI068617), the Center For HIV/AIDS Vaccine Immunology (U19-AI067854), the University of North Carolina Center For AIDS Research (P30-AI50410), and to R.S. (R37-AI44667) and M.S.C. (R37-DK49381). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Graham SM, Holte SE, Peshu NM, Richardson BA, Panteleeff DD, et al. (2007) Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 21: 501–507. [PubMed]
2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734–739. [PubMed]
3. Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, et al. (2000) Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 14: 117–121. [PubMed]
4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493–505. [PMC free article] [PubMed]
5. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921–929. [PubMed]
6. Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, et al. (2011) Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 3: 77ra29. [PMC free article] [PubMed]
7. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, et al. (2006) Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 20: 85–92. [PubMed]
8. Del Romero J, Castilla J, Hernando V, Rodriguez C, Garcia S (2010) Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ 340: c2205. [PMC free article] [PubMed]
9. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092–2098. [PMC free article] [PubMed]
10. Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, et al. (2011) HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 25: 473–477. [PMC free article] [PubMed]
11. Eshleman SH, Hudelson SE, Redd AD, Wang L, Debes R, et al. (2011) Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis 204: 1918–1926. [PMC free article] [PubMed]
12. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871–1879. [PubMed]
13. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552–7557. [PubMed]
14. Drummond AJ, Rambaut A (2007) BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 7: 214. [PMC free article] [PubMed]
15. Giorgi EE, Funkhouser B, Athreya G, Perelson AS, Korber BT, et al. (2010) Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics 11: 532. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science